Premium
Radiation treatment of carcinoma of the cervix with extension into the endometrium. A reappraisal of its significance
Author(s) -
Prempree Thongbliew,
Patanaphan Vinita,
Viravathana Thavinsakdi,
Sewchand Wilfred,
Cho Young K.,
Scott Ralph M.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820515)49:10<2015::aid-cncr2820491012>3.0.co;2-3
Subject(s) - medicine , cervix , stage (stratigraphy) , endometrial cancer , radiation therapy , cervical cancer , endometrium , cancer , carcinoma , metastasis , survival rate , oncology , gynecology , surgery , paleontology , biology
During the period from 1969–1974, 561 patients with proven invasive squamous cell carcinoma of the cervix were treated by irradiation only in the Department of Radiation Therapy, University of Maryland Hospital. Of these, 82 patients were identified as having D & C positive for squamous cell cancer present in the curettings with or without endometrial tissue. Clinical staging was done using FIGO guidelines and the treatment of endometrial extension was the same as with regular cervical cancer. Of 82 cases who are eligible for a minimum five‐year follow‐up, the absolute five‐year survival is as follows: Stage I, 68% (17/25); Stage II, 62% (18/29); Stage III, 40% (10/25); Stage IV, 0% (0/3). The most interesting features are the local and distant failures in Stage I and II disease. Local failure in Stage I and II in this study is in line with other series. Distant metastasis, however, occurs at the rate of 20% in Stage I between 1–2 years after treatment (as compared to the control of 5%). In Stage II, the distant disease increases to 24% with a substantial number of local failure with distant metastasis. Based on our findings and others, it seems appropriate to suggest D & C be done routinely in order to identify the extension of cancer into the endometrium and treat them properly. Also it appears appropriate to re‐examine our policy of the treatment to minimize both local and distant failures with suggestions outlined in Schema I and II along with possibility of a future chemotherapeutic management to minimize the distant disease.